Influenza virus vaccine trivalent - Novavax

Drug Profile

Influenza virus vaccine trivalent - Novavax

Alternative Names: CadiFlu-S; Influenza virus-like particle vaccine trivalent - Novavax; Novavax trivalent vaccine; Seasonal influenza VLP vaccine - Novavax; VLP-based trivalent seasonal influenza vaccine - Novavax

Latest Information Update: 23 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novavax
  • Developer CPL Biologicals; Novavax
  • Class Influenza virus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 17 Nov 2016 Launched for Influenza virus infections (Prevention) in India (IM)
  • 06 Aug 2015 Phase-II development is ongoing in USA and Australia
  • 31 Dec 2014 Phase-III clinical trials in Influenza virus infections (Prevention) in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top